William Blair Analysts Increase Earnings Estimates for Assembly Biosciences, Inc. (ASMB)

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Equities research analysts at William Blair boosted their FY2017 EPS estimates for Assembly Biosciences in a report released on Monday. William Blair analyst Y. Xu now anticipates that the biopharmaceutical company will earn ($2.95) per share for the year, up from their previous forecast of ($3.40). William Blair also issued estimates for Assembly Biosciences’ Q4 2017 earnings at ($0.66) EPS, FY2018 earnings at ($3.18) EPS and FY2019 earnings at ($3.55) EPS.

ILLEGAL ACTIVITY WARNING: This news story was first published by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.thestockobserver.com/2017/11/15/william-blair-analysts-increase-earnings-estimates-for-assembly-biosciences-inc-asmb.html.

Several other research firms also recently issued reports on ASMB. BidaskClub raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Jefferies Group LLC initiated coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They set a “buy” rating and a $50.00 price target for the company. Zacks Investment Research downgraded Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th.

Assembly Biosciences (ASMB) opened at $33.06 on Wednesday. Assembly Biosciences has a one year low of $11.07 and a one year high of $36.31.

In related news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total transaction of $29,550.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 19.60% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Lyon Street Capital LLC increased its position in Assembly Biosciences by 9.7% during the 3rd quarter. Lyon Street Capital LLC now owns 149,443 shares of the biopharmaceutical company’s stock worth $5,219,000 after purchasing an additional 13,243 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in Assembly Biosciences during the 3rd quarter worth about $577,000. OxFORD Asset Management LLP increased its position in Assembly Biosciences by 26.6% during the 3rd quarter. OxFORD Asset Management LLP now owns 66,227 shares of the biopharmaceutical company’s stock worth $2,220,000 after purchasing an additional 13,925 shares in the last quarter. Wells Fargo & Company MN increased its position in Assembly Biosciences by 148.5% during the 3rd quarter. Wells Fargo & Company MN now owns 25,600 shares of the biopharmaceutical company’s stock worth $894,000 after purchasing an additional 15,300 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Assembly Biosciences by 6.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock worth $5,944,000 after purchasing an additional 11,412 shares in the last quarter. Hedge funds and other institutional investors own 62.19% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply